It Doesn't Matter What Happens with Greece, Gold, or the Fed

Having trouble viewing this issue? Click here.

Monday, June 27th, 2011 Dear Wealth Daily Reader, It doesn't matter what happens with Greece, gold, or the Fed when you have exclusive rights to a technology that can regenerate limbs and organs. No longer the stuff of bad sci-fi flicks, this biotech company can use cells from your body to grow any part needed... Organs damaged or lost to disease, limbs lost to accidents and war — all able to be regrown. Phase II FDA trials are underway. But the government agency is already so impressed with the technology, it awarded "seven years of U.S. marketing exclusivity... as well as additional incentives in the form of tax credits for clinical research expenses." This is for real. Learn about it today. To your wealth,  Steve Christ Editor, Wealth Daily http://www.angelnexus.com/o/web/27458 You can manage your subscription and get our privacy policy here. Wealth Daily, Copyright © 2011, Angel Publishing LLC, P.O. Box 84905, Phoenix, AZ 85071. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Wealth Daily does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this newsletter. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.